直接血运重建失败后临界肢体缺血患者接受间接血管体血运重建联合前列地尔辅助治疗的结局
本研究在本中心评估前列地尔(前列腺素E1)作为间接血运重建辅助治疗,用于直接血运重建失败的临界肢体缺血患者。120例腹股沟下外周动脉疾病患者接受血管内血运重建,前列地尔组术后静脉输注前列地尔40 μg(溶于100 ml生理盐水,2小时,每12小时一次,共6天)。结果显示前列地尔组ABI从基线0.45±0.175升至研究结束时0.65±0.216(差值0.2±0.041,P=0.08),保肢58/60例(96.7%)。
要点
- 前列地尔组ABI从基线0.45±0.175升至0.65±0.216,差值0.2±0.041,P=0.08。
- 前列地尔组1个月一期通畅率93.3%,3个月和6个月通畅率均为92.9%。
- 前列地尔组60例中58例(96.7%)保肢,2例(3.3%)研究结束前接受膝下截肢。
核心结论
- 结果表明前列地尔作为间接血管体血运重建的辅助治疗,对因临界肢体缺血导致组织缺损的患者具有疗效和安全性。
研究设计与样本
- 本研究在本中心纳入120例腹股沟下外周动脉疾病合并临界肢体缺血、直接血运重建尝试失败的患者,所有血运重建术均为血管内手术。
- 前列地尔组平均年龄63.41±12.52岁,男性36例(60%),女性24例(40%)。
- 合并糖尿病患者随访中位时间2年,无糖尿病患者随访中位时间2.5年。
主要发现
- 前列地尔组基线ABI均值±标准差为0.45±0.175,研究结束时ABI均值±标准差为0.65±0.216,与基线差值为0.2±0.041(P=0.08,原文注明<0.05为显著)。
- 前列地尔组1个月一期通畅率为93.3%,3个月和6个月通畅率均为92.9%。
- 对照组基线ABI均值±标准差为0.68±0.22,研究结束时ABI均值±标准差为0.69±0.23,与基线差值为0.01±0.01(P>0.05,原文注明无显著意义)。
- 对照组1个月通畅率为89%,3个月和6个月通畅率均为75%。
- 前列地尔组无流出道血管组从10例(16.7%)降至4例(6.67%),单流出道血管组从40例(66.7%)降至36例(60%),双流出道血管组从10例(16.7%)升至20例(33.3%)。
关键数值与推荐
- 前列地尔组术后立即经静脉输注前列地尔40 μg(溶于100 ml生理盐水),输注时间2小时,每12小时一次,共6天。
- 前列地尔组未进行足部动脉弓干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study was carried out to assess the effectiveness of alprostadil (prostaglandin E1) when used as an adjuvant therapy with indirect revascularization in patients with critical limb ischemia (CLI) after the failure of direct revascularization (DR). METHODS: At our centers, 120 patients suffering from infrainguinal peripheral arterial disease with CLI underwent a failed trial of DR procedure, all revascularization procedures were endovascular. Median follow-up was 2 years and 2.5 years for patients with and without diabetes mellitus (DM). In the alprostadil group, the mean age was 63.41 ± 12.52; 36 (60%) for males and 24 (40%) for females. Post-endovascular intervention alprostadil was administrated immediately postoperatively by intravenous infusion of 40 μg alprostadil diluted in 100 ml of normal saline, over 2 hr every 12 hr for 6 days. RESULTS: In the alprostadil group, the mean ± standard deviation (SD) of the baseline ankle-brachial index (ABI) was 0.45 ± 0.175, while the mean ± SD of ABI at the end of our study was 0.65 ± 0.216 with a difference from the baseline of 0.2 ± 0.041 (P value = 0.08, <0.05 meaning that it is significant). Our 1-month primary patency rate was 93.3%, while our 3- and 6-month patency rate was 92.9%. In the control group, the mean ± SD of the baseline ABI was 0.68 ± 0.22, while the mean ± SD of ABI at the end of our study was 0.69 ± 0.23 with a difference from the baseline of 0.01 ± 0.01 (P value >0.05 meaning that it is nonsignificant) 1-month patency rate was 89%, while 3- and 6-month patency rate was 75%. When we compared the patient's leg vessels before and after our intervention, we found that the percentage of the no-runoff-vessels group decreased from 10 (16.7%) to 4 (6.67%). One-runoff-vessel group percentage dropped from 40 (66.7%) to 36 (60%), whereas, in the two-runoff-vessel group, the percentage increased from 10 (16.7%) to 20 (33.3%). We evaluate leg arteries; we do no pedal arch intervention in the alpostradil group. Out of the total of 60 patients, limb salvage occurred in 58 (96.7%) patients, and 2 (3.3%) patients underwent below-the-knee amputation before the study ended. CONCLUSIONS: Our results show the efficacy and safety of alprostadil as an adjuvant therapy with indirect angiosomal revascularization in patients with tissue loss due to CLI.
引用
- Alhewy MA, Abdo EM, Ghazala EAE, et al. Outcomes of Alprostadil As an Adjuvant Therapy with Indirect Angiosomal Revascularization in Patients with Critical Limb Ischemia after Failure of Direct Revascularization. Ann Vasc Surg. 2024. PMID: 38431199. doi:10.1016/j.avsg.2023.12.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。